Bisphosphonates in renal osteodystrophy

被引:13
作者
Fan, SLS [1 ]
Cunningham, J [1 ]
机构
[1] St Bartholomews & Royal London Hosp, Dept Nephrol, London E1 1BB, England
关键词
D O I
10.1097/00041552-200109000-00006
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
The present review considers the role that bisphosphonates might have in patients with renal failure. Although bisphosphonates are widely used to reduce fracture risk in patients with osteoporosis, few studies have documented their effect in patients with renal osteodystrophy. The pathogenesis of bone loss after renal transplantation and the role of the recently identified osteoprotegerin/receptor activating nuclear factor-kappaB system is described. Inhibition of bone resorption may prove beneficial when high bone turnover is present, but there are potential drawbacks to widespread use of bisphosphonates, These issues are discussed, with emphasis placed on reports published within the past 18 months. Curr Opin Nephrol Hypertens 10:581-588, (C) 2001 Lippincott Williams & Wilkins.
引用
收藏
页码:581 / 588
页数:8
相关论文
共 70 条
[1]   Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis [J].
Adachi, JD ;
Bensen, WG ;
Brown, J ;
Hanley, D ;
Hodsman, A ;
Josse, R ;
Kendler, DL ;
Lentle, B ;
Olszynski, W ;
SteMarie, LG ;
Tenenhouse, A ;
Chines, AA .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (06) :382-387
[2]   LOSS OF REGIONAL BONE-MINERAL DENSITY IN THE 1ST 12 MONTHS FOLLOWING RENAL-TRANSPLANTATION [J].
ALMOND, MK ;
KWAN, JTC ;
EVANS, K ;
CUNNINGHAM, J .
NEPHRON, 1994, 66 (01) :52-57
[3]   Bone mineral density in haemodialysis patients: A comparative study of dual-energy X-ray absorptiometry and quantitative ultrasound [J].
Arici, M ;
Erturk, H ;
Altun, B ;
Usalan, C ;
Ulusoy, S ;
Erdem, Y ;
Sivri, A ;
Yasavul, U ;
Turgan, C ;
Caglar, S .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2000, 15 (11) :1847-1851
[4]   Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures [J].
Black, DM ;
Cummings, SR ;
Karpf, DB ;
Cauley, JA ;
Thompson, DE ;
Nevitt, MC ;
Bauer, DC ;
Genant, HK ;
Haskell, WL ;
Marcus, R ;
Ott, SM ;
Torner, JC ;
Quandt, SA ;
Reiss, TF ;
Ensrud, KE .
LANCET, 1996, 348 (9041) :1535-1541
[5]   osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification [J].
Bucay, N ;
Sarosi, I ;
Dunstan, CR ;
Morony, S ;
Tarpley, J ;
Capparelli, C ;
Scully, S ;
Tan, HL ;
Xu, WL ;
Lacey, DL ;
Boyle, WJ ;
Simonet, WS .
GENES & DEVELOPMENT, 1998, 12 (09) :1260-1268
[6]   Bone disease in patients with long-term renal transplantation and normal renal function [J].
Carlini, RG ;
Rojas, E ;
Weisinger, JR ;
Lopez, M ;
Martinis, R ;
Arminio, A ;
Bellorin-Font, E .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2000, 36 (01) :160-166
[7]   Posttransplant bone disease: Evidence for a high bone resorption state [J].
Cayco, AV ;
Wysolmerski, J ;
Simpson, C ;
Mitnick, MA ;
Gundberg, C ;
Kliger, A ;
Lorber, M ;
Silver, D ;
Basadonna, G ;
Friedman, A ;
Insogna, K ;
Cruz, D ;
Bia, M .
TRANSPLANTATION, 2000, 70 (12) :1722-1728
[8]   Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone [J].
Coco, M ;
Rush, H .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2000, 36 (06) :1115-1121
[9]   The effect of raloxifene on risk of breast cancer in postmenopausal women - Results from the MORE randomized trial [J].
Cummings, SR ;
Eckert, S ;
Krueger, KA ;
Grady, D ;
Powles, TJ ;
Cauley, JA ;
Norton, L ;
Nickelsen, T ;
Bjarnason, NH ;
Morrow, M ;
Lippman, ME ;
Black, D ;
Glusman, JE ;
Costa, A ;
Jordan, VC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (23) :2189-2197
[10]   BONE-DENSITY AT VARIOUS SITES FOR PREDICTION OF HIP-FRACTURES [J].
CUMMINGS, SR ;
BLACK, DM ;
NEVITT, MC ;
BROWNER, W ;
CAULEY, J ;
ENSRUD, K ;
GENANT, HK ;
PALERMO, L ;
SCOTT, J ;
VOGT, TM .
LANCET, 1993, 341 (8837) :72-75